Cooperation between NorDiag and Molzym
"Short term, this agreement will have a positive effect on the operating income for the Arrow instrument. On a strategic level, collaboration with partners regarding integrated tests opens up a range of opportunities for NorDiag", comments CEO of NorDiag, Mårten Wigstøl.
The system will be launched in Q2-2010. NorDiag's contribution is the Arrow instrument, while Molzym is contributing with reagents. The system will be sold under the brand name of Molzym. NorDiag will distribute on a non exclusive basis the system in North America, and on an exclusive basis in the Nordic countries, while Molzym will sell the system through their distributor network in the rest of the world. The agreement also covers potential agreements with strategic partners. NorDiag and Molzym have agreed upon a fixed split of revenue and profit on revenues from potential strategic partners.
Other news from the department business & finance
These products might interest you
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.